Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axe Compute Inc., formerly Predictive Oncology Inc., filings document the issuer's completed strategic transformation into a GPU compute infrastructure and digital asset treasury company. Form 8-K disclosures cover operating and financial results, capital raised for the digital asset treasury strategy, and material-event reporting tied to enterprise AI compute infrastructure.
The filings also document governance changes, executive appointments and employment arrangements, shareholder voting matters, capital-structure disclosures, and contract announcements involving dedicated NVIDIA GPU clusters and AI-focused storage for large-scale model training, fine-tuning, and inference workloads.
Predictive Oncology Inc. entered into a Securities Purchase Agreement with an accredited investor for a private placement of 543,544 shares of common stock at $0.76 per share, for gross proceeds of approximately $413,093. The deal closed on August 26, 2025.
The company agreed to limits on issuing additional common stock or equivalents and granted the investor a 100% participation right in future equity offerings through October 31, 2025. It plans to use net proceeds for working capital and general corporate purposes and must file a resale registration statement within 90 days, relying on Section 4(a)(2) and Rule 506(b) exemptions.
Predictive Oncology Inc. is calling a special stockholder meeting on September 19, 2025 to vote on three key items. The first is a 1‑for‑15 reverse stock split intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price and support its continued listing after receiving delisting notices and a compliance extension through December 8, 2025. Based on 10,892,657 shares outstanding as of the record date, this would reduce outstanding shares to roughly 726,177, with holders receiving one whole share in lieu of any fractional share. The second proposal seeks approval under Nasdaq rules to issue up to $10,000,000 of common stock under a Standby Equity Purchase Agreement with Yorkville, which could exceed the 20% issuance cap and may be deemed a change of control. The third proposal would allow adjournment of the meeting to solicit more votes if needed.
Predictive Oncology Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company used this filing to formally furnish the press release, which is included as Exhibit 99.1. This gives investors access to the detailed quarterly performance information through the attached exhibit rather than within the body of the report.
Predictive Oncology applies AI and a proprietary biobank of 150,000+ tumor samples to support oncology drug discovery and now operates as a single segment focused on AI-driven cancer-therapy development after reclassifying its Birmingham and Eagan businesses to discontinued operations.
The company reported total assets of $3.44M and total liabilities of $5.09M as of June 30, 2025, producing a stockholders' deficit of $(1.65M). Cash and cash equivalents were $506,078. For the six months ended June 30, 2025 the company recorded revenue of $112,992, a net loss of $4.51M (continuing operations loss of $4.26M), and net cash used in continuing operating activities of $4.28M. The company sold its Eagan assets for $625,000 (plus assumed liabilities) and closed related discontinued operations.
Management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing. Nasdaq notified the company of noncompliance but a Hearings Panel granted an extension through December 8, 2025. Subsequent events include a standby equity purchase agreement providing the right to sell up to $10.0M of common stock subject to conditions and a proposed 1-for-15 reverse stock split subject to stockholder approval.
Predictive Oncology (POAI) has scheduled a 2025 Special Meeting to vote on three board-backed items:
- Reverse Stock Split 1-for-15 – designed to lift the share price above Nasdaq’s US$1.00 minimum and remedy bid-price and equity deficiencies. Nasdaq has granted an extension until 8 Dec 2025.
- Nasdaq Proposal – authorize issuance of up to US$10 million in common stock under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. Yorkville can purchase shares over 36 months at VWAP minus 4 %, potentially exceeding the 19.99 % “Exchange Cap.”
- Adjournment Proposal – permits the meeting to be postponed to secure sufficient votes.
The reverse split will consolidate every 15 shares into one, reduce the shares outstanding accordingly and round up fractional entitlements. While the move should improve marketability and preserve the Nasdaq listing, it increases the pool of authorized but unissued shares, raising dilution and anti-takeover concerns. The SEPA offers flexible working-capital financing, yet further share sales will dilute existing holders and depend on shareholder approval to lift the cap.
Failure to pass Proposals 1 or 2 risks delisting and limits access to the full SEPA facility. The board unanimously recommends voting FOR all three proposals.